TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

PURPOSE: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53 profiling in liquid biopsies from metastatic castration-resistant prostate cancer (mCRPC) patients starting a new line of AR signalling inhibitors (ARSi). EXPERIMENTAL DESIGN: Between March 2014 and April 2017, we...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: De Laere, Bram, Oeyen, Steffi, Mayrhofer, Markus, Whitington, Tom, van Dam, Pieter-Jan, Van Oyen, Peter, Ghysel, Christophe, Ampe, Jozef, Ost, Piet, Demey, Wim, Hoekx, Lucien, Schrijvers, Dirk, Brouwers, Barbara, Lybaert, Willem, Everaert, Els, De Maeseneer, Daan, Strijbos, Michiel, Bols, Alain, Fransis, Karen, Beije, Nick, de Kruijff, Inge, van Dam, Valerie, Brouwer, Anja, Goossens, Dirk, Heyrman, Lien, Van den Eynden, Gert, Rutten, Annemie, Del Favero, Jurgen, Rantalainen, Mattias, Rajan, Prabhakar, Sleijfer, Stefan, Ullén, Anders, Yachnin, Jeffrey, Grönberg, Henrik, Van Laere, Steven, Lindberg, Johan, Dirix, Luc
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6330086/
https://ncbi.nlm.nih.gov/pubmed/30209161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1943
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki